IN8bio Inc. has unveiled a corporate presentation highlighting their advancements in the development of gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for oncology and autoimmune diseases. The company emphasizes the potential of γδ T cells, described as "Nature's CAR-T" cells, to directly kill cancer cells and orchestrate a broad immune response. IN8bio's T cell therapies aim to provide durable cancer remissions, with some patients experiencing over three years of progression-free survival. The presentation points out the precision and safety of γδ T cells, noting their lower rates of adverse events such as cytokine release syndrome and neurotoxicity. IN8bio's DeltExTM platform addresses key challenges in cell therapy and TCE development, while their γδ TCE construct is designed to efficiently deplete target cells and promote γδ T cell expansion. You can access the full presentation through the link below.